Aussie8 – Lifestyle
Author:
Opus Genetics, Inc.
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
May 7, 2026
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
May 4, 2026
Opus Genetics to Participate in Leading Medical Conferences in May 2026
April 27, 2026
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
April 6, 2026
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
March 24, 2026
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
March 10, 2026